Drugs / Otlertuzumab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01644253 | Sep 2012 → Feb 2020 | B-cell chronic lymphocytic leukemia, peripheral T-cell lymphoma, not otherwise specified | Aptevo Therapeutics | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT01317901 | May 2011 → Apr 2013 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Aptevo Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00614042 | Jan 2008 → Dec 2011 | B-cell chronic lymphocytic leukemia | Aptevo Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01188681 | Sep 2010 → Dec 2014 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Aptevo Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2013-01-02 | Emergent BioSolutions | Regulatory Emergent’s TRU-016 for CLL Receives Orphan Medicinal Product Designation from European Commission emergentbiosolutions.com ↗ |
| 2011-12-01 | Emergent BioSolutions | Regulatory Emergent BioSolutions Receives Orphan Drug Designation for Its TRU-016 Protein Therapeutic for the Treatment of Chronic Lymphocytic Leukemia emergentbiosolutions.com ↗ |
| 2010-12-06 | Emergent BioSolutions | Results Emergent BioSolutions Presents Positive Data from Its TRU-016 Program at American Society of Hematology Meeting emergentbiosolutions.com ↗
In an oral presentation given yesterday, results from the study show that TRU-016 demonstrates favorable response rates and is generally well-tolerated in patients with chronic lymphocytic leukemia (CLL). |
All press releases naming this drug 14 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Otlertuzumab | “Otlertuzumab (TRU-016) is a novel humanized anti-CD37 protein therapeutic.” PMID 25146490 ↗ Aug 2014 |
| Known as | TRU-016 | “Otlertuzumab (TRU-016) is a novel humanized anti-CD37 protein therapeutic.” PMID 25146490 ↗ Aug 2014 |
| Modality | Monoclonal antibody | — CHEMBL3039539 ↗ |
| Modality | Protein / enzyme biologic | “Otlertuzumab (TRU-016) is a novel humanized anti-CD37 protein therapeutic.” PMID 25146490 ↗ Aug 2014 |
| Route | Intravenous | “TRU-016 at 20 mg/kg, weekly by IV infusion x 2 cycles” NCT01188681 ↗ |
| Target | CD37 | “Otlertuzumab (TRU-016) is a novel humanized anti-CD37 protein therapeutic.” PMID 25146490 ↗ Aug 2014 |